Discontinued — last reported Q4 '24
mirokidney — Milestone payment to be made
United Therapeutics mirokidney — Milestone payment to be made remained flat by 0.0% to $13.50M in Q4 2024 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $13.50M to $13.50M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests higher future capital outflows tied to project progress, while a decrease indicates either the completion of payment obligations or a reduction in the scope of development milestones.
Detailed definition
This metric represents the future financial obligations triggered by the achievement of specific development, regulatory...
Peer comparison
Similar to contingent consideration or milestone-based R&D liabilities found in other biotechnology and pharmaceutical companies focused on long-term pipeline development.
uthr_segment_mirokidney_milestone_payment_to_be_madeHistorical Data
| FY'23 | FY'24 | |
|---|---|---|
| Value | $54.00M | $54.00M |
| YoY Change | — | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's mirokidney — milestone payment to be made?
- United Therapeutics (UTHR) reported mirokidney — milestone payment to be made of $13.50M in Q4 2024.
- How has United Therapeutics's mirokidney — milestone payment to be made changed year-over-year?
- United Therapeutics's mirokidney — milestone payment to be made decreased by 0.0% year-over-year, from $13.50M to $13.50M.
- What does mirokidney — milestone payment to be made mean?
- The total amount of future payments the company is contractually obligated to pay upon reaching specific project development goals.